Taken together, viral infection can be evaluated as a potential predictor of PD-1/PD-L1 inhibitors; however, the correlation between viral infection and treatment efficacy needs to be confirmed by additional basic research and large-scale clinical trials. This evidence concerns the gene CD274 and viral infectious disease.